ArticleJournal for immunotherapy of cancer2018

Durable regression of Medulloblastoma after regional and intravenous delivery of anti-HER2 chimeric antigen receptor T cells.

Anandani Nellan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.